Department of Anaesthesiology, University Hospital Basel
Basel, 4031, Switzerland
NCT Number: NCT05485480
The aim of this double blind, randomised controlled non-inferiority trial is to compare the antinociceptive efficiency of an opioid-sparing and a conventional opioid-based anaesthesia protocol with the help of the CEcertificated Pain Monitoring Device (PMD-200).
Looking for future studies?
Notify Me18 year and older
All sexes
Interventional
Not applicable
Basel, 4031, Switzerland
Opioids have been an integral part of general anaesthesia. They are effective in preventing perception of noxious stimuli and ensure intraoperative haemodynamic stability. However, opioids are associated with a number of unwanted side effects (e.g. nausea and vomiting, sedation, ileus, respiratory depression, increased postoperative pain and morphine consumption and hyperalgesia). To minimise these side effects, there has been an interest in developing opioid-sparing anaesthesia protocols. Recently, analgesia nociception monitoring devices have become available. The aim of this double blind, randomised controlled non-inferiority trial is to compare the antinociceptive efficiency of an opioid-sparing and a conventional opioid-based anaesthesia protocol with the help of the CEcertificated Pain Monitoring Device (PMD-200). Patients scheduled to receive general surgical, gynaecological or urological laparoscopic surgery will be randomised into one of the two study groups. Study group A will be anaesthetised with an opioid-sparing protocol and study group B will be anaesthetised with a conventional opioid-based protocol. Intraoperative nociception will be evaluated with PMD-200. Postoperative visits will take place in recovery, 4-5h after surgery and then twice a day. In recovery, the amount of opioids and ketamine needed, pain, postoperative nausea and vomiting (PONV) and the time until the patient is fit for discharge according to the Aldrete score will be assessed. At the 4-5h postoperative visit, the amount of opioids and ketamine needed, maximum pain at rest and at mobilisation, incidence of PONV, mobilisation, micturition and sedation level will be assessed. At the twice daily follow up visits, amount of opioids and other analgesic drugs needed, pain at rest and at mobilisation, gastrointestinal function, quality of night's sleep, incidence of PONV, level of sedation and fitness for discharge home will be assessed. On day one after surgery, the perceived quality of recovery will be assessed with the QoR40 questionnaire.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
In addition to propofol as a hypnotic and rocuronium as a muscle relaxant, patients in the conventional opioid-based group will receive the following drugs: Remifentanil and Fentanyl
In addition to propofol as a hypnotic and rocuronium as a muscle relaxant, patients in the opioid-sparing group will receive Ketamine, Fentanyl, Lidocaine, Magnesium, Clonidine, Remifentanil
Time frame: From the timepoint of skin incision until skin closure (within 1 day)
The PMD-200 device consists of a finger probe which continuously assesses pulse rate, pulse rate variability, pulse wave amplitude, skin conductance level, skin conductance fluctuations, skin temperature, and finger motion. A value of 0 corresponds to no pain and a value of 100 to maximal pain. A value will be measured every minute from the timepoint of skin incision until skin closure.
Time frame: Every 15 minutes in recovery until patient discharge to the ward (within 1 day)
Fitness for discharge to ward is checked every 15 minutes with the Aldrete score. The Aldrete score assigned a number of 0, 1, or 2 to 5 variables: activity, respiration, circulation, consciousness, and color. A score of 9 out of 10 is considered adequate for discharge from the recovery.
Time frame: From the stay in recovery before discharge from the ward (average of 1 week)
Amount of morphine needed
Time frame: From the stay in recovery before discharge from the ward (average of 1 week)
Amount of ketamine needed
Time frame: From the stay in recovery before discharge from the ward (average of 1 week)
Change in pain score at rest by numeric rating scale (to assess pain severity using a 0-10 scale, with zero meaning "no pain" and 10 meaning "the worst pain imaginable)
Time frame: From the stay in recovery before discharge from the ward (average of 1 week)
Change in pain score at movement by numeric rating scale (to assess pain severity using a 0-10 scale, with zero meaning "no pain" and 10 meaning "the worst pain imaginable)
Time frame: From the first postoperative day until discharge from ward (average of 1 week)
Quality of night's sleep assessed with a verbal numerical scale from 0 (very poor quality of sleep) to 10 (excellent quality of sleep)
Time frame: From the stay in recovery before discharge from the ward (average of 1 week)
Occurrence of postoperative nausea and vomiting (PONV)
Time frame: At 4 hours and then twice daily until discharge from the ward (average of 1 week)
Change in level of sedation
Time frame: At the first postoperative day
40-item questionnaire that provides a global score and subscores across five dimensions: patient support, comfort, emotions, physical independence, and pain
Time frame: From the stay in recovery before discharge from the ward (average of 1 week)
Time to return of gastrointestinal function as defined as the time from the end of surgery to the first passage of flatus and to the first bowel movement
Time frame: From the stay in recovery before discharge from the ward (average of 1 week)
Time to return of spontaneous micturition
University Hospital, Basel, Switzerland
Other
Nociception Level During Opioid-sparing Anaesthesia Versus Conventional Opioid-based Anaesthesia: a Randomised Controlled Non-inferiority Trial
Acronym: NOL_Basel
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07059429
Agnosia, Analgesia
Moscow, Russia
View Trial DetailsNCT07066306
Agnosia, Analgesia
Istanbul, Fatih, Turkey (Türkiye)
View Trial DetailsNCT05999734
Agnosia, Analgesia
Tanta, Gharbia Governorate, Egypt
View Trial DetailsNCT02471898
Agnosia, Analgesia
Pasadena, California, United States
View Trial Details